The economic impact of chronic obstructive pulmonary disease
The economic impact of chronic obstructive pulmonary disease
复制标题
慢性阻塞性肺疾病的经济影响
DOI：
--
复制
发表时间：
2002
影响因子：
3.2
通讯作者：
D. Hilleman
中科院分区：
文献类型：
--
作者：
M. Faulkner;D. Hilleman
与慢性支气管炎和肺气肿(统称为慢性阻塞性肺疾病(COPD))相关的成本负担很大。这种疾病不仅影响患者，也影响照顾者和社会。据估计，美国目前有1600万人被诊断为慢性阻塞性肺疾病，其中大多数人患有慢性支气管炎。与这种疾病相关的死亡率正在上升，其在女性人口和老年人中的流行率也在上升。目前，它是美国和世界范围内第四大最常见的死因。到目前为止，唯一被证明具有成本效益的疾病治疗方法是停止或预防吸烟，这是COPD最常见的单一原因，以及接种疫苗以防止流感和肺炎球菌感染。住院和相关费用是这种疾病患者最大的医疗支出。就COPD治疗的直接医疗费用而言，长期氧疗也是最昂贵的干预措施之一，尽管它可能具有成本效益，因为它对死亡率有积极影响。事实上，到目前为止，氧疗是唯一被证明可以降低COPD死亡率的干预措施。适当的药物治疗有可能降低资源利用率，但似乎不会影响死亡率。同样，肺康复计划似乎在生活质量方面对患者有利；然而，长期成本效益和对死亡率的影响尚未阐明。间接成本也占该疾病经济负担的很大一部分，但要量化要困难得多。
The cost burden associated with chronic bronchitis and emphysema, collectively known as chronic obstructive pulmonary disease (COPD), is large. The disease impacts not only on patients but caregivers and society as well. An estimated 16 million people in the US are currently diagnosed with COPD, the majority having chronic bronchitis. Mortality associated with this disease is on the upswing, as is its prevalence in the female population and the elderly. It is currently the fourth most common cause of death both in the US and worldwide. To date, the only proven cost-effective therapies for the disease are the cessation or prevention of smoking, which is the single most common cause of COPD, and vaccination to prevent influenza and pneumococcal infection. Hospitalisation and associated costs represent the greatest healthcare expenditures for people with the disease. Long-term oxygen therapy is also among the most costly interventions in terms of total money spent on direct medical costs for COPD treatment, although it is probably cost-effective because of its positive impact on rates of mortality. In fact, oxygen therapy is the only intervention to date that has been shown to decrease death rates due to COPD. Appropriate treatment with medication has the potential to decrease resource utilisation but does not appear to affect death rates. Similarly, pulmonary rehabilitation programs appear to benefit patients in terms of quality of life; however, long-term cost-effectiveness and effects on mortality have yet to be elucidated. Indirect costs also contribute a substantial part of the economic burden of the disease but are significantly harder to quantify.
影响因子：
3.8
作者：
TENGS, TO;ADAMS, ME;GRAHAM, JD
通讯作者：
GRAHAM, JD
茶碱和异丙托溴铵治疗慢性阻塞性肺疾病的成本效益比较分析。
影响因子：
9.6
作者：
Jubran,A;Gross,N;Ramsdell,J;Simonian,R;Schuttenhelm,K;Sax,M;Kaniecki,DJ;Arnold,RJ;Sonnenberg,FA
通讯作者：
Sonnenberg,FA